Tenofovir exalidex

Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC50s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV[1][2][3].

Product Specifications

CAS Number

[911208-73-6]

Product Name Alternative

CMX-157

UNSPSC

12352005

Target

HBV; HIV; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/tenofovir-exalidex.html

Purity

99.82

Solubility

Ethanol : 1 mg/mL (ultrasonic)

Smiles

NC1=C2N=CN(C[C@H](OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C)C2=NC=N1

Molecular Formula

C28H52N5O5P

Molecular Weight

569.72

References & Citations

[1]Lanier ER, et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother. 2010;54 (7) :2901-2909.|[2]Gallay P, et al. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLoS One. 2019;14 (6) :e0217433. Published 2019 Jun 10.|[3]Painter GR, et al. Evaluation of hexadecyloxypropyl-9-R-[2- (Phosphonomethoxy) propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections [published correction appears in Antimicrob Agents Chemother. 2007 Dec;51 (12) :4538]. Antimicrob Agents Chemother. 2007;51 (10) :3505-3509.